biostudies-literatureJarsberg LGNational Institute of Allergy and Infectious DiseasesNIAID NIH HHSNational Institutes of HealthNIGMS NIH HHSe0250586https://www.ebi.ac.uk/biostudies/studies/S-EPMC8099102biostudies-literatureUnknown16(5)<h4>Introduction</h4>Contemporary phase 2 TB disease treatment clinical trials have found that microbiologic treatment responses differ between African versus non-African regions, the reasons for which remain unclear. Understanding host and disease phenotypes that may vary by region is important for optimizing curative treatments.<h4>Methods</h4>We characterized clinical features and the serum proteome of phase 2 TB clinical trial participants undergoing treatment for smear positive, culture-confirmed TB, comparing host serum protein expression in clinical trial participants enrolled in African and Non-African regions. Serum samples were collected from 289 participants enrolled in the Centers for Disease Control and Prevention TBTC Study 29 (NCT00694629) at time of enrollment and at the enPloS oneNutritional markers and proteome in patients undergoing treatment for pulmonary tuberculosis differ by geographic region.PMC8099102P41 GM103493R01 AI1045891R01AI104589GM103493Sigal GBWeiner MHSmith RDJarsberg LGWright ATJacobs JMShi TGritsenko MAKedia KWendler JLewinsohn DMPiehowski PDNahid PKeane JfalseNutritional markers and proteome in patients undergoing treatment for pulmonary tuberculosis differ by geographic region.<h4>Introduction</h4>Contemporary phase 2 TB disease treatment clinical trials have found that microbiologic treatment responses differ between African versus non-African regions, the reasons for which remain unclear. Understanding host and disease phenotypes that may vary by region is important for optimizing curative treatments.<h4>Methods</h4>We characterized clinical features and the serum proteome of phase 2 TB clinical trial participants undergoing treatment for smear positive, culture-confirmed TB, comparing host serum protein expression in clinical trial participants enrolled in African and Non-African regions. Serum samples were collected from 289 participants enrolled in the Centers for Disease Control and Prevention TBTC Study 29 (NCT00694629) at time of enrollment and at the en2021-01-01T00:00:00Z20212026-04-07T14:39:17.203Z2025-02-19T02:15:24.947ZS-EPMC80991023395106610.1371/journal.pone.0250586